Publication of Clinical Studies
were more likely to be published than those funded by private companies (9 of 16 [56%]; P = .006). Among published studies, 3 primary outcome results were discordant, but only 1 discordance changed the interpretation of the study's findings; the remaining published results were concordant with results reported within FDA reviews ( Table 2) .
Discussion | Among studies supporting FDA approval of novel, high-risk cardiovascular devices between January 2011 and December 2013, 8 of 10 reported their results in the peerreviewed biomedical literature. Although this rate is consistent with the publication rate among pivotal trials supporting new drug approvals, 3 it is substantially higher than the rate of 49% observed for trials supporting FDA-approved, high-risk cardiovascular devices between January 2000 and December 2010. 4 Furthermore, nearly all publications in our study presented results in a manner concordant with FDA reviews, which was an improvement from prior study of medical device research results reporting. Editor's Note page 554 
